Revive Therapeutics (RVV.V) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19.
Today, the Company announced it has entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine.
“We are very excited to commercialize a potential world-first patented diagnostic solution for long COVID, which may have the ability to help millions of people globally in being correctly diagnosed so that appropriate medical interventions and treatments can be offered to improve quality of life and reduce the economic burden experienced by countries,” said Michael Frank, CEO of Revive.
“Currently, long COVID is diagnosed based on a previous diagnosis of COVID-19 and a clinical assessment that includes a health history and a physical examination. The development of a rapid long COVID diagnostic test is crucial for not only identification and treatment, but also to reduce unnecessary medical testing and health care expenditures,” said Dr. Douglas Fraser, Lawson Scientist, Critical Care Physician at London Health Sciences Centre, and Professor at Western University’s Schulich School of Medicine & Dentistry.
Under the terms of the agreement, Revive Diagnostics Inc., a subsidiary of Revive Therapeutics, has gained exclusive worldwide rights to intellectual property for the development and commercialization of novel blood biomarkers that characterize long COVID disease.
Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. More than 200 symptoms have been identified with impacts on multiple organ systems — including fatigue, brain fog, difficulty breathing, and cardiovascular symptoms ranging from chest pain and arrhythmias to sudden cardiac death—but it remains a diagnosis of exclusion with an unknown biological basis.
The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms. David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the total economic cost of long COVID could be as much as $3.7 trillion.
Revive Therapeutics and Lawson will work together in completing the development of a qELISA laboratory test kit and a lateral flow assay point of care device for rapid testing of long COVID. Revive Therapeutics will evaluate the potential of the long COVID test as a companion to Bucillamine – a potential treatment for long COVID disease.
The stock is testing its major support zone around $0.025. The stock should see buyers enter here to hold support. A daily close above $0.04 would be a good start for potential upwards momentum. The major resistance zone comes in at the $0.06 zone.
